Theragnostics inks AstraZeneca agreement

AuntMinnie.com staff writers

Sep 4, 2019

Molecular radiotherapy developer Theragnostics said it has signed an intellectual property agreement with AstraZeneca.

The agreement allows Theragnostics to develop radiotherapy based on radionuclide-labeled poly (ADP-ribose) polymerase (PARP) inhibitors, a class of oncology drugs that block the PARP enzyme, which cancer cells use in response to DNA damage.

2026 02 13 Port Fractures Thumbnail

Study questions routine use of radiotherapy after bone surgery

February 13, 2026

Siemens, Northwestern to collaborate on precision cancer care

February 9, 2026

Radiologist Breast Imaging Computer Screen

Public-private EU consortium awarded $18M for cancer research

February 4, 2026

ASTRO and ESTRO mark World Cancer Day

February 4, 2026

Study questions routine use of radiotherapy after bone surgery

Findings suggest a possible hazard associated with postoperative radiotherapy.

February 13, 2026

2026 02 13 Port Fractures Thumbnail

Siemens, Northwestern to collaborate on precision cancer care

By AuntMinnie.com staff writers

The two organizations plan to establish a global center of excellence in theranostics.

February 9, 2026

Public-private EU consortium awarded $18M for cancer research

By AuntMinnie.com staff writers

The PreciseOnco consortium has been awarded $17.6 million from the EU’s Innovative Health Initiative for precision cancer treatment.

February 4, 2026

Radiologist Breast Imaging Computer Screen

ASTRO and ESTRO mark World Cancer Day

By AuntMinnie.com staff writers

Today’s radiotherapy is a far more precise, effective, and patient-centered treatment than ever before, according to the groups.

February 4, 2026

Nucs AI establishes medical advisory board

By AuntMinnie.com staff writers

Nucs AI has formed its medical advisory board to ensure the company's AI theranostics tech is aligned with clinical practice.

January 29, 2026

Ai Abstract Researcher (1)

ASTRO launches national radiopharmaceutical therapy training centers

By AuntMinnie.com staff writers

ASTRO has launched a national program creating Authorized User Training Centers for radiopharmaceutical therapy education.

January 29, 2026

Radiotherapy 400

Nuclidium wins patent for Cu-61-based radiodiagnostic program

By AuntMinnie.com staff writers

The patent protects the copped-61 (Cu-61)-based diagnostic as well as its use in combination with Cu-67.

January 26, 2026

Cu Copper Periodic Table Element Adobe Digital Equilibrium

Elekta secures U.S. FDA 510(k) clearance for Evo

By AuntMinnie.com staff writers

The company is moving forward with Elekta Evo CT-Linac.

January 16, 2026

Radiation Therapy Suite 400 l Tms5 W Hgx Q

Alliance for Clinical Trials in Oncology launches prostate cancer trial

By AuntMinnie.com staff writers

The phase III trial, called RECIPROCAL, will include 1,500 patients with metastatic, castration-resistant prostate cancer.

January 5, 2026

Radiation Therapy Suite

What are Pluvicto discontinuation rates in a real-world setting?

There is a critical need to predict nonresponders and potential discontinuers prior to treatment.

January 5, 2026

Prostate Imaging

ASTRO introduces new research foundation approach

By AuntMinnie.com staff writers

ASTRO is renaming its research foundation and highlighting new aims for the institute to go along with the update.

January 2, 2026

Proton therapy effective for patients with oropharyngeal cancer

The treatment targets tumors with charged particles rather than the high-energy x-rays of photon therapy.

December 15, 2025

Page 1 of 468